Helix Biopharma Responds To Penta Financial Services AG

AURORA, ON, Dec. 22 /PRNewswire-FirstCall/ - Helix BioPharma Corp. has learned from press reports that International Penta Financial Services AG ("Penta") intends to issue a dissident information circular in association with the Annual General and Special Meeting of Helix shareholders scheduled for January 23, 2007.

"It would be premature to respond to Penta's press release without reviewing their rationale for the statements made by them in such release," said Don Segal, President of Helix BioPharma. "We assume that the reasons for Penta's position will be set out fully in their pending dissident information circular, as will the historical relationships of Penta and its Chairman, Herald A.M.A. Janssen, to Helix BioPharma."

"I must state for the record that I have no arrangements whatsoever with Penta regarding my directorship," said Jack Kay, Director of Helix BioPharma and Chief Operating Officer of Apotex Inc. "I am in full support of Helix's current management and their director nominees. In my opinion, my fellow incumbent directors and I have diligently worked to advance the interests of all Helix shareholders. In that regard, I am very much looking forward to the year ahead and the milestones that management and the existing Board have set for themselves in 2007, as outlined in our current Annual Report. I am also very much looking forward to the addition to our Board of Directors of Dr. Gordon M. Lickrish, who has been nominated by management as an additional independent director."

A copy of Helix BioPharma's current Annual Report and Information Circular for the January 23, 2007 meeting can be found on SEDAR at www.sedar.com, and at Helix's website at www.helixbiopharma.com. Requests for a hard copy of the Annual Report or Information Circular can also be made to Georgeson.

Please visit our website for regular updates at www.helixbiopharma.com

This News Release contains certain forward-looking statements regarding the Company's 2007 milestones. Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous risks and uncertainties, including those described in Helix's latest Annual Information Form filed with the Canadian Securities Regulatory Authorities at www.sedar.com.

CONTACT: North American Toll Free Number: 1-866-288-9745; Outside NorthAmerica Collect: (416) 642-7018; (x)Toll Free - European: 00800 1020 1010;European Collect: +44 (0) 117 378 5993. (x)Australia; Austria; Belgium;Denmark; Finland; France; Germany; Hong Kong; Ireland; Israel; Italy;Netherlands; New Zealand; Norway; Spain; Sweden; Switzerland; Thailand;United Kingdom